Stelo is intended for adults 18 and older who do not use insulin, including people with Type 2 diabetes who are treating their condition with oral medications. The monitoring device is a small sensor that tracks glucose levels in real time and is paired with an application on a user’s smartphone or other device. Measurements and trends are updated in the app every 15 minutes.
“CGMs can be a powerful tool to help monitor blood glucose,” Jeff Shuren, MD, director of the FDA’s center for devices and radiological health, said in a news release. “Today’s clearance expands access to these devices by allowing individuals to purchase a CGM without the involvement of a healthcare provider.”
Dexcom said there are approximately 25 million people in the U.S. with Type 2 diabetes who do not take insulin. The company offers another CGM that is available only with a prescription. Stelo is expected to be available for purchase without a prescription this summer.
The company did not mention pricing details in its announcement about Stelo’s FDA clearance.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
